
BRIGHT MINDS BIOSCIENCES INC.
BRIGHT MINDS BIOSCIENCES INC. (DRUG)
WebsitePrice
Market cap
Next catalystAdditional data including long-term outcomes throughout 2026BMB-101 — BREAKTHROUGH absence-seizure cohort · Phase 2 dataCompany release ↗
Cash
Chart & Events
Core Clinical
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Clinical
Upcoming clinical milestones
Other pipelines
Financial position
Company funding outlook
Upcoming milestones
Financial history
Annual trends
| Reported item | ||||
|---|---|---|---|---|
Reported shares and borrowings
Ownership and institutions
| Status | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|